Dr. Matthew Taub, a board-certified physician specializing in internal medicine, hematology, and oncology, possesses more than 20 years of clinical experience. In addition to his work on several medical committees, Dr. Matthew Taub holds membership in the American Society of Clinical Oncology (ASCO).
For over a decade, ASCO has released Clinical Cancer Advances, an annual report detailing the year’s most significant advances in cancer treatment. The 2018 release brings focus to several Food and Drug Administration-approved therapies for their impact in the fight against cancer.
In 2017, the FDA approved pembrolizumab for use in patients with certain types of metastatic tumors. The immunotherapy drug is first in a line of tissue-agnostic therapies, treatments that work based on a tumor’s biomarkers, to be approved.
The report also chronicles improvements in targeted therapies for lung, breast, and bladder cancers and reviews the promising effects of radiotherapy and tumor-treating fields on aggressive forms of brain cancer.